Form 4: Catalyst Pharmaceuticals Executive Vice President & CFO Michael Kalb Reports Stock Transactions
SEC Form 4 Filing
Michael Kalb, Executive Vice President & CFO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On January 2, 2025, Michael Kalb, Executive Vice President & CFO of Catalyst Pharmaceuticals, reported transactions involving the company's common stock.
- Kalb acquired 7,138 shares of common stock through the vesting of restricted stock units.
- Simultaneously, 2,941 shares were withheld by Catalyst Pharmaceuticals to satisfy applicable withholding taxes.
- Following these transactions, Kalb directly owns 4,197 shares of Catalyst Pharmaceuticals common stock and 475,699 derivative securities.
- The restricted stock units vest in equal tranches annually from January 1, 2025, to January 1, 2029, with shares delivered within sixty days of vesting.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't indicate any significant positive or negative sentiment.
Future Outlook
The restricted stock units will continue to vest in equal tranches annually from January 1, 2026, to January 1, 2029.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of stock transactions (vesting of restricted stock units and tax withholding). |
| 01/03/2025 | Date of signature for the Form 4 filing. |
| January 1, 2025, 2026, 2027, 2028 and 2029 | Vesting dates for the restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.